CASE STUDY: Managing the costs and health of a patient with rheumatoid arthritis
Putting Patients First: A Collaborative Approach to Managing Rheumatoid Arthritis and Reducing Costs.
Insights Archive
Leveraging Therapy Management in Your Health Plan
ClearScript & Fairview Specialty Pharmacy’s Innovative Partnership Gain expert insight into Fairview and ClearScript’s approach to therapy management. Learn how…
The PBMs Role in Mental Health Care
ClearScript’s VP of Clinical & Account Services, Nicole Christian and Lynn Branch, PBM Client Commitments Director, break down how PBMs are evolving to support mental health care. Learn how your plan can improve access, affordability, and outcomes.
In Your Corner
From tackling specialty drug costs to delivering member-focused solutions, Kyle breaks down what it really means to have a PBM in your corner.
Big PBM Markups
What the FTC Reports Reveal—And Where ClearScript Stands The FTC’s interim reports on PBMs highlight a troubling trend: sky-high markups…
How PBMs Help Schools Cut Costs & Stay Compliant
In this episode of Coffee with ClearScript, we’ll unpack how PBMs can help school districts lower costs, ensure transparency, meet regulatory requirements, and support complex union-driven benefit designs.
Plan design development to achieve results.
A well-aligned plan isn’t just cost-effective; it’s built with purpose, supporting your broader healthcare objectives and ensuring long-term impact.
6 Ways ClearScript Supports You and Your Members During Open Enrollment—and Beyond
Open enrollment can be a hectic season for HR teams and a confusing time for employees. But it’s also a…
Drug Spotlight: Yesintek and Selarsdi
YESINTEK (ustekinumab-kfce)Manufacturer: BioconLaunch Date: 2/24/2025 SELARSDI (ustekinumab-aekn)Manufacturer: Alvotech/TevaLaunch Date: 1/2025 YESINTEK & SELARSDI are biosimilars of reference product STELARA (Ustekinumab),…
Don’t let your PBM off the hook!
ClearScript experts Nicole Christian, PharmD, Vice President of Clinical Account Services, and Mackenzie Pfeiffer, Director of Account Management, and Vice President of Sale, Kyle D. Johnson, will share an inside look at the latest PBM challenges, including recent negative press, the rebate debate (including the role of international sourcing), the GLP-1 controversy, and the rise of biosimilars.
Drug Spotlight: Suzetrigine
suzetrigine (VX-548) Manufacturer: Vertex Approval Date: 1/30/2025 Suzetrigine possesses a novel mechanism of action as a voltage-gated sodium channel inactivator…
20 Years Strong: Celebrating ClearScript’s Legacy of Stewardship to Our Clients
This year marks a significant milestone for ClearScript: 20 years of trusted stewardship in pharmacy benefits. For two decades, we…